Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs
Nucleoside, nucleotide, and base analogs have been in the clinic for decades to treat both
viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy …
viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy …
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Serum CA 19‐9 is the only FDA approved biomarker recommended for use in the routine
management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies …
management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies …
Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets
Nucleoside and nucleobase analogs are currently used in the treatment of solid tumors,
lymphoproliferative diseases, viral infections such as hepatitis and AIDS, and some …
lymphoproliferative diseases, viral infections such as hepatitis and AIDS, and some …
Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive
Pancreatic cancer is the fourth leading cause of cancer-related death in the United States.
There has been minimal progress with regard to cancer-specific outcomes in recent …
There has been minimal progress with regard to cancer-specific outcomes in recent …
Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells
W Hagmann, R Jesnowski, JM Löhr - Neoplasia, 2010 - Elsevier
Gemcitabine is widely used as first-line chemotherapeutic drug in the treatment of pancreatic
cancer. Our previous experimental chemotherapy studies have shown that treatment of …
cancer. Our previous experimental chemotherapy studies have shown that treatment of …
Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities
Adenosine compartmentalization has a profound impact on immune cell function by
regulating adenosine localization and, therefore, extracellular signaling capabilities, which …
regulating adenosine localization and, therefore, extracellular signaling capabilities, which …
[HTML][HTML] Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models
Materials and Methods BxPC-3, MiaPaca-2 and Panc-1 cells were cultured in standard and
fasting mimicking culturing condition to evaluate the effects of gemcitabine. Pancreatic …
fasting mimicking culturing condition to evaluate the effects of gemcitabine. Pancreatic …
Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway
T Namba, R Kodama, S Moritomo, T Hoshino… - Cell death & …, 2015 - nature.com
Pancreatic cancer is one of the most difficult malignancies to treat owing to the rapid
acquisition of resistance to chemotherapy. Gemcitabine, a first-line treatment for pancreatic …
acquisition of resistance to chemotherapy. Gemcitabine, a first-line treatment for pancreatic …
Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug …
DB Kell - The FEBS Journal, 2013 - Wiley Online Library
Despite the sequencing of the human genome, the rate of innovative and successful drug
discovery in the pharmaceutical industry has continued to decrease. Leaving aside …
discovery in the pharmaceutical industry has continued to decrease. Leaving aside …
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge
SW Hung, HR Mody, R Govindarajan - Cancer letters, 2012 - Elsevier
Clinical refractoriness to nucleoside analogs (eg, gemcitabine, capecitabine) is a major
scientific problem and is one of the main reasons underlying the extremely poor prognostic …
scientific problem and is one of the main reasons underlying the extremely poor prognostic …